Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Vaxcyte, Inc. — fact timeline
Source-grounded facts extracted from Vaxcyte, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. Olivier Brandicourt was appointed as Director at Vaxcyte, Inc..
“On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.”
John P. Furey was appointed as Class II director at Vaxcyte, Inc..
“the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.”
Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2024.
“Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.”
Vaxcyte, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.